Case report of recurrent fibromatosis with laryngeal involvement: Treatment based on network analyses of NGS data
- Authors:
- Nathan Lloyd
- Jonathan Kopel
- Sanjay Awasthi
- Joehassin Cordero
View Affiliations
Affiliations: Department of Surgery, Division of Heme/Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA, Department of Internal Medicine, Division of Heme/Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
- Published online on: February 1, 2022 https://doi.org/10.3892/mco.2022.2506
-
Article Number:
73
-
Copyright: © Lloyd
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Aggressive fibromatosis (AF) is a rare, benign neoplasm originating from musculoaponeurotic stromal structures characterized by aggressive growth and infiltration of local tissues. To date, only six previous cases of AF involving the larynx have been reported. The present case was that of a 70‑year‑old female patient with a 5‑year history of hoarseness and an enlarging neck mass consistent with aggressive recurrent fibromatosis. MRI displayed a large, solid mass arising from the left anterior cervical space displacing the trachea and upper airway to the right. At one year after the initial radical resection, the patient presented with recurrence. A second radical excision was performed not including a laryngectomy. Radiation therapy was considered for possible local treatment to prevent subsequent tumor recurrence. According to the literature, AF has recurrence rates of up to 40‑70% within 18 months. There is only sparse literature to guide treatment. Using the mutations detected in the patient's AF tissue, an Ingenuity Pathway Analysis (IPA) was used to guide treatment of the recurrence. In the present case, the IPA analysis indicated the use of pazopanib to treat the patient's cancer. In general, surgery appears to be the treatment of choice for head and neck AF, but the management of recurrence is controversial.
View Figures |
Figure 1
|
 |
Figure 2
|
 |
Figure 3
|
 |
Figure 4
|
 |
Figure 5
|
 |
Figure 6
|
 |
Figure 7
|
 |
Figure 8
|
View References
|
1
|
Wang W, Koirala U, Ma S, Liu G, Ding M, Hu
X and Lei D: Age-based treatment of aggressive fibromatosis in the
head and neck region. J Oral Maxillofac Surg. 72:311–321.
2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shinohara S, Suehiro A, Kikuchi M, Harada
H, Kishimoto I and Imai Y: A case of desmoid tumor co-existing with
recurrent squamous cell carcinoma in the larynx. Auris Nasus
Larynx. 44:365–369. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Prabhu R, Natarajan A, Shenoy R and Vaidya
K: Aggressive fibromatosis (desmoid tumour) of the head and neck: A
benign neoplasm with high recurrence. BMJ Case Rep.
2013(bcr2013200156)2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Simões-Pereira J, Cabrera RA and Leite V:
A case of thyroid fibromatosis, a rare lesion of this gland.
Endocrinol Diabetes Metab Case Rep. 2016:16–0019. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Salas S, Dufresne A, Bui B, Blay JY,
Terrier P, Ranchere-Vince D, Bonvalot S, Stoeckle E, Guillou L, Le
Cesne A, et al: Prognostic factors influencing progression-free
survival determined from a series of sporadic desmoid tumors: A
wait-and-see policy according to tumor presentation. J Clin Oncol.
29:3553–3558. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Specchia ML, Frisicale EM, Carini E, Di
Pilla A, Cappa D, Barbara A, Ricciardi W and Damiani G: The impact
of tumor board on cancer care: Evidence from an umbrella review.
BMC Health Serv Res. 20(73)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cheng L, Pandya PH, Liu E, Chandra P, Wang
L, Murray ME, Carter J, Ferguson M, Saadatzadeh MR,
Bijangi-Visheshsaraei K, et al: Integration of genomic copy number
variations and chemotherapy-response biomarkers in pediatric
sarcoma. BMC Med Genomics. 12 (Suppl 1):23:2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cancer Genome Atlas Research Network:
Electronic address: simpleelizabeth.demicco@sinaihealthsystem.ca
and Cancer Genome Atlas Research Network. Comprehensive and
integrated genomic characterization of adult soft tissue sarcomas.
Cell. 171:950–965. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Highlights of Prescribing Information -
Votrient (pazopanib) tablets (2009). White Oak, Maryland: Food and
Drug Admini-stration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022465s021lbl.pdf.
|
